Nivegacetor Pharmacology: Preclinical Data for an Alzheimer's Disease Treatment Candidate

617.2 KB PDF contains in vitro and in vivo pharmacology data for nivegacetor (RG6289), a gamma secretase modulator. Lothar Lindemann authored this supplementary file, which details studies on amyloid-beta peptide modulation, selectivity, and effects on ADAD mutations. The file was last updated on 2026-05-28.

Use Cases

• Evaluate drug candidate potency based on in vitro Aβ42/Aβ40 reduction and Aβ37/Aβ38 increase data
• Assess compound selectivity based on the described Notch-1 and broad pharmacological target profiling
• Analyze treatment impact on genetic mutations based on data from PSEN1 E280A and PSEN2 N141I ADAD models
• Plan clinical trial imaging based on results showing no interference with [3H]florbetaben plaque binding

Strengths

• Data includes results from both in vitro cell line studies and in vivo APPSwe transgenic mouse models
• File is licensed under CC-BY-4.0, allowing for broad reuse and sharing
• Description provides specific details on tested mutations (PSEN1 E280A, PSEN2 N141I) and pharmacological targets

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The 617.2 KB size suggests a limited data scope, likely a summary document rather than a raw dataset

Provenance

Source

figshare

Collection Method

Likely contains summarized results from preclinical laboratory studies.

Freshness

Last updated 2026-05-28 09:07:41; freshness should be verified